The week was marked by significant presentations at the American Society of Hematology (ASH) meeting, highlighting advancements in the treatment of chronic leukemia and lymphoma. AstraZeneca unveiled new data demonstrating the benefits of combining venetoclax with its drug Calquence for chronic leukemia. Meanwhile, Sino-American biotech BeiGene concentrated its efforts on presenting findings related to Brukinsa, targeting leukemia and lymphoma.
On the regulatory front, Dutch gene therapy company uniQure saw its shares surge following the announcement of a clear path forward for its Huntington’s disease candidate, AMT-130. However, not all news was positive; US biotech Q32 Bio experienced a dramatic 75% drop in its share price after releasing Phase IIA trial results for bempikibart in alopecia areata, which were described as 'messy.' Similarly, Keros Therapeutics faced challenges, deciding to halt parts of its Phase II program involving cibotercept for pulmonary hypertension.
